H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) Inc on Wednesday, setting a price target of $70, which is approximately 34.93% above the present share price of $51.88.
Fein expects Stoke Therapeutics Inc to post earnings per share (EPS) of -$0.41 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Stoke Therapeutics, with an average price target of $67.75.
The analysts price targets range from a high of $83 to a low of $53.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$13.71 million. The company's market cap is $1.9 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.0% and a 52.76% success rate.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.